An interventional study of Male Pelvic Floor Rehabilitation #1 in Erectile Dysfunction, Urinary Incontinence and Premature Ejaculation, sponsored by Dream Video LLC. Not yet recruiting. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Dream Video LLC · Not applicable, Interventional, and Treatment
Phase I
G128 Study Objective
The ischiocavernosus (IC) and bulbospongiosus (BS) muscles are vital components of the superficial perineal layer, serving as the foundation for male sexual health and performance. These muscles play a primary role in achieving and maintaining erections by compressing the veins to trap blood within the erectile tissues. Furthermore, they are responsible for the rhythmic contractions necessary for ejaculation and the physiological sensations associated with orgasm.
Beyond their role in sexual function, these muscles provide critical structural support to the pelvic floor and assist in urinary control. By working in tandem, the IC and BS muscles ensure penile rigidity while stabilizing the surrounding pelvic structures. Maintaining the strength and coordination of these muscles is essential for overall reproductive health and the prevention of pelvic floor dysfunction.
The primary objective of this clinical trial is to evaluate the clinical efficacy and therapeutic potential of Exercise G128 in strengthening the male pelvic floor musculature. Furthermore, the study aims to establish a comprehensive safety profile for Exercise G128 during active participation. The research seeks to address the following core investigative questions:
To what extent does Exercise G128 improve the tonicity and contractile strength of the IC and BS muscles?
What is the incidence and nature of adverse medical events or physiological stressors reported by participants while performing the Exercise G128 protocol?
Researchers will conduct a comparative analysis, benchmarking the physiological outcomes of Exercise G128 against existing clinical data regarding the efficacy of traditional Kegel exercises.
Participant Requirements:
Adhere to a structured regimen, performing Exercise G128 four times weekly over a one-month intervention period.
Attend bi-weekly telehealth consultations via video conferencing for supervised clinical assessments, progress monitoring, and physiological testing.
Maintain a detailed daily log documenting functional progress, as well as any instances of physical exertion or soreness that necessitated a temporary cessation of the exercise protocol.
UPDATE:
The G128 inventor and user scheduled an appointment with a Certified Pelvic Rehab Practitioner, who has over 10 years of experience treating complex diagnoses and pelvic impairments. During the appointment, a male pelvic floor muscle test was performed using Rehabilitative Ultrasound Imaging (RUSI).
Ultrasound Findings (suprapubic RUSI): Muscle bulk is visually above average compared to clinician's clinical experience; good bilateral muscle mass noted with asymmetry as described.
Voluntary Contraction / Coordination: Patient demonstrated visible pelvic floor lift on ultrasound with volitional kegel contraction.
Contraction quality: good lift observed; clinician noted contraction quality as above average relative to clinical experience.
G128 Study Objective
The primary purpose of this clinical investigation is to evaluate the physiological efficacy of the targeted G128 exercise protocol in enhancing the structural integrity and contractile strength of the pelvic floor musculature. This study specifically aims to measure hypertrophy and functional improvements within the Ischiocavernosus and Bulbospongiosus muscles following a standardized training period. By establishing these metrics, the research seeks to validate the protocol's impact on core pelvic stability.
Utilizing quantitative assessment tools, this research will determine whether the G128 regimen yields a statistically significant increase in pelvic muscle tone and endurance compared to baseline measurements. The findings may support the implementation of this regimen as a viable, non-invasive therapeutic intervention for patients experiencing various forms of pelvic floor dysfunction. Ultimately, the study strives to provide a data-driven foundation for advanced rehabilitative practices.
701 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
This study's planned enrollment of 100 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Dream Video LLC is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Male Pelvic Floor Rehabilitation #1
Execute the G128 exercise for four consecutive days, followed by a scheduled three-day recovery period. This specific training cycle should be repeated consistently over a 30-day duration to achieve optimal results. Maintaining this frequency ensures a proper balance between physical exertion and necessary muscle repair.
This study aims to compare the number of participants experiencing treatment-related adverse events versus those with positive treatment outcomes.
Time frame: From enrollment to the end of treatment at 4 weeks.
Proportion of Patients Achieving Quantifiable Improvements in Pelvic Floor Muscle Strength Following a One-Month Treatment Protocol.
Time frame: From enrollment to the end of treatment at 4 weeks.
No study locations are listed for this record.
Plan to share: Yes — The deidentified individual participant data underlying the results reported in this article will be made available for research purposes. This data sharing period will commence 9 months after the date of publication and will conclude 36 months following the article's release. This timeline ensures sufficient time for primary analysis while promoting transparency and collaborative scientific inquiry. Researchers interested in accessing the data should submit a formal proposal to dream@dreamholdingsllc.com. All requests will be subject to a rigorous review process conducted by an independent committee to ensure the scientific merit and ethical integrity of the proposed study. Approved scientists will be required to sign a data use agreement before any information is transmitted.
Supporting information: Clinical study report
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.